ARK Invest’s Latest Moves: CoreWeave and Kratos Purchases Highlight February 27 Trading

ARKs CoreWeave purchase occurred during a session where the stock declined 19%. The downturn followed fourth-quarter earnings that demonstrated robust revenue growth but revealed expanding losses and capital expenditures that exceeded market expectations.

By purchasing shares during the selloff, ARK appears to interpret the market reaction as temporary volatility rather than fundamental business deterioration. CoreWeave operates in the AI computing infrastructure space, which has experienced substantial demand expansion.

CoreWeave maintains a Moderate Buy rating among Wall Street analysts. With eleven Buy ratings and eight Hold ratings, the consensus price target of $114.18 suggests potential upside of approximately 43.5% from current trading levels.

ARK Scales Back Teradyne and Rocket Lab Holdings

Regarding portfolio reductions, ARK divested 38,773 Teradyne shares valued at $12.9 million across several ETFs. Teradyne manufactures semiconductor testing systems and industrial automation equipment. This transaction continues ARKs recent pattern of decreasing its Teradyne exposure.

ARK also liquidated 46,921 shares of Rocket Lab valued at approximately $3.4 million. The space technology company had recently announced quarterly performance that surpassed both earnings and revenue projections, yet shares declined roughly 5% on Friday.

Rocket Lab disclosed robust launch operations and an expanding order backlog. Nevertheless, the inaugural launch of its larger Neutron rocket was delayed until late 2026, potentially contributing to investor disappointment.

Additional Portfolio Adjustments in Biotech and Technology

ARK disposed of 46,389 shares of Roku valued at $4.3 million from its ARKK fund. The rationale for this divestment was not publicly disclosed.

Within the biotechnology sector, ARK acquired 459,525 shares of Generate Biomedicines valued at $7.4 million via its ARKG fund. Simultaneously, the fund sold 39,423 shares of Ionis Pharmaceuticals for $3.2 million.

ARK liquidated 10,590 Deere & Co shares for $6.6 million and reduced its Guardant Health position by 27,334 shares valued at $2.7 million.

Minor transactions included a reduction of 205,211 PagerDuty shares for $1.5 million and an acquisition of 14,097 Brera Holdings shares valued at approximately $15,600.

The CoreWeave and Kratos acquisitions represented ARKs two most significant individual transactions on February 27, with combined value exceeding $42 million.

The post ARK Invests Latest Moves: CoreWeave and Kratos Purchases Highlight February 27 Trading appeared first on Blockonomi.